Sebastian Sommer, Maximilian Schmutz, Tina Schaller, Patrick Mayr, Sebastian Dintner, Bruno Märkl, Ralf Huss, M Monika Golas, Michaela Kuhlen, Frank Jordan, Rainer Claus, Bernhard Heinrich
BACKGROUND: Inflammatory myofibroblastic tumor (IMTs) are rare mesenchymal neoplasms with slow growth. Resection is considered as therapeutic standard, with chemotherapy being insufficiently effective in advanced disease. ALK translocations are present in 50% of cases, ROS1 fusions (YWHAE::ROS1, TFG::ROS1) are extremely rare. Here, we present a case with TFG::ROS1 fusion and highlight the significance of molecular tumor boards (MTBs) in clinical precision oncology for post-last-line therapy...
November 11, 2023: Cancer reports